Raymond Stevens, Structure Therapeutics CEO

Struc­ture's oral GLP-1 pro­duces com­pa­ra­ble weight loss to Lil­ly's oral can­di­date

Struc­ture Ther­a­peu­tics’ oral GLP-1 hit all end­points in a pair of mid-stage stud­ies eval­u­at­ing weight loss and safe­ty, send­ing its stock …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.